Search

for
Search:

GlossaryTrametinib

medication that inhibits MEK protein to treat specific cancers

Trametinib is a medication used to treat certain types of cancer, specifically melanoma with a BRAF V600E or V600K mutation. It works by inhibiting a protein called MEK, which is part of a pathway that helps cancer cells grow and divide. By blocking this protein, trametinib can slow down or stop the growth of cancer cells.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 72 results

research Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib

10 citations , September 2016 in “Journal of cutaneous medicine and surgery”

Patients on dabrafenib and trametinib for melanoma often experience skin side effects.

research Hair and Nail Adverse Events During Treatment with Targeted Therapies for Metastatic Melanoma

32 citations , May 2016 in “European journal of dermatology/EJD. European journal of dermatology”

Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.

research MIG6 Is MEK-Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma

April 2016 in “Journal of Investigative Dermatology”

Decreasing MIG6 can increase the movement and invasiveness of MEK-inhibited mutant NRAS melanoma, particularly when stimulated by EGF.

research Pustular Eruption in a Patient Treated With Trametinib

December 2025 in “Pediatric Dermatology”

Trametinib can cause skin issues, but they can often be managed without stopping the drug.

research Identifying the Target Cells and Mechanisms of Merkel Cell Polyomavirus Infection

133 citations , May 2016 in “Cell Host & Microbe”

Human dermal fibroblasts are the main cells targeted by a virus that can cause a deadly skin cancer, and a certain inhibitor can effectively block this infection.

View more "trametinib" in research →

Community Join

0 / 0 results

— no results